Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 19];7(2):s176. Available from: https://skin.dermsquared.com/skin/article/view/2001